Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 1/20 | 0.67 |
| ▸ | TLR7 | Q9NYK1 | 13/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isatoribine SCHEMBL12808801 | 1.00 | PNP (0.67) | PNPTLR7MEN1KMT2ACYP3A4 | |
| Isatoribine SCHEMBL1758185 | 1.00 | PNP (0.67) | PNPTLR7MEN1KMT2ACYP3A4 | |
| Isatoribine SCHEMBL6975944 | 1.00 | PNP (0.67) | PNPTLR7MEN1KMT2ACYP3A4 | |
| Isatoribine SCHEMBL8664086 | 1.00 | PNP (0.67) | PNPTLR7MEN1KMT2ACYP3A4 | |
| Isatoribine SCHEMBL10148062 | 1.00 | PNP (0.67) | PNPTLR7MEN1KMT2ACYP3A4 | |
| Isatoribine SCHEMBL12112066 | 1.00 | PNP (0.67) | PNPTLR7MEN1KMT2ACYP3A4 | |
| Isatoribine SCHEMBL23475855 | 1.00 | PNP (0.67) | PNPTLR7MEN1KMT2ACYP3A4 | |
| Isatoribine SCHEMBL10117797 | 1.00 | PNP (0.67) | PNPTLR7MEN1KMT2ACYP3A4 | |
| Isatoribine SCHEMBL1276851 | 0.99 | PNP (0.65) | PNPTLR7MEN1KMT2ACYP3A4 | |
| SCHEMBL6976713 | 0.91 | TLR7 (0.57) | PNPTLR7MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0961775-B1 | PURINE L-NUCLEOSIDES, ANALOGS AND USES THEREOF | ICN PHARMACEUTICALS (US) | 2004-07-14 | — | — | EP | disclosed |
| US-6509320-B1 | To treat an infection, an infestation, a neoplasm, or an autoimmune disease | ICN PHARMACEUTICALS, INC. | 2003-01-21 | — | — | US | disclosed |
| US-20020058635-A1 | Purine L-nucleosides, analogs and uses thereof | AVERETT DEVRON R (US) | 2002-05-16 | — | — | US | disclosed |
| EP-1072607-A2 | Purine L-nucleosides, analogs and uses therof | ICN Pharmaceuticals, Inc. (US) | 2001-01-31 | — | — | EP | disclosed |
| EP-0961775-A2 | PURINE L-NUCLEOSIDES, ANALOGS AND USES THEREOF | ICN Pharmaceuticals, Inc. (US) | 1999-12-08 | — | — | EP | disclosed |
| WO-1998016184-A2 | PURINE L-NUCLEOSIDES, ANALOGS AND USES THEREOF | ICN PHARMACEUTICALS, INC. (US) | 1998-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058635-A1 | Purine L-nucleosides, analogs and uses thereof | PNP, NUDT1, TYMP | PNP 1/4885TLR7 66/4885MEN1 1889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.